Source: Dr. Bill Cherniak, Co-Founder & CEO of Rocket Doctor Inc., video interview,
Operating figures attributed to Cherniak below are unaudited management commentary; the Q2 2026 MD&A has not yet been filed. Where I cite filed disclosure, I say so.
I’ve argued for a while that this market is pricing the before picture: Rocket Doctor spent two to three years building payer infrastructure the tape gave it zero credit for, and the gap between ~21 million covered lives and the revenue actually recognized against them was the whole opportunity.
Cherniak’s Q2 update is the first quarter where you can watch that gap start to close in real time. Here’s what stood out.
1. The supply side: 80+ physicians, and they’re paying to get in
Rocket Doctor has scaled to over 80 signed physicians across the United States (be mindful not all have been credentilized yet, therefore not all are seeing patints and/or generting revenue more that below).
The number I care about more is US$500, the upfront fee each physician pays Rocket Doctor to process their credentialing with insurance networks. That’s the tell. Doctors paying out of pocket to join a platform is a fundamentally different signal than doctors signing a free-tier agreement, because it filters the merely curious out of the count. And the company got there without expensive recruiting firms. Physicians are coming organically, looking for autonomy over their schedules and the ability to capture reimbursement rates they actually generate rather than handing them to a corporate employer.
Credentialing takes three to six months. That’s the constraint I’ve called the binding one on this business from the beginning not patient demand, not payer access, credentialing throughput. Which means a meaningful slice of those 80+ physicians is dry powder: capacity already signed and paid for that structurally unlocks over the coming quarters without any new sales effort.
That’s the part the market isn’t modelling. The doctors are already in the pipeline. The revenue from them just hasn’t arrived yet.
2. The demand side: ~4,000 visits, 200% growth
Roughly 4,000 U.S. patient visits in Q2, up about 200% over Q1.
For context on the slope: U.S. operations were essentially at zero last December. The filed Q1 MD&A disclosed about 1,200 completed U.S. visits in April 2026, up 69% month over month. Getting to 4,000 for the quarter off that base, while credentialing was still the gate on supply, suggests demand isn’t the problem. Patient routing and the booking experience are working.
Worth holding in mind for how you read the next print: under the company’s stated U.S. policy, revenue is recognized on actual cash receipt, not on service delivery. Medicare and Medicaid claims settle 45 to 90 days out. So most of Q2’s visit volume lands in Q3 and Q4 revenue, not Q2’s. I’ve said before I read that as accounting conservatism rather than a warning sign, but it does mean the reported revenue line will always trail the operating reality by a quarter or so. If you’re waiting for the visit curve and the revenue curve to move together, you’ll be early to worry and late to act.
3. CAC is falling, and the margin mix is telling you the U.S. business is real
Cherniak noted that customer acquisition cost has dropped considerably in every state they operate in, even through the 200% volume surge. CAC isn’t a disclosed metric, so I can’t independently check it, but it’s consistent with what you’d expect once brand recognition and payer in-network status start doing the work paid acquisition used to do.
Management is also being disciplined about how it spends. Rather than burning cash on conventional ad buys, the company secured a high-visibility partnership with Rick Ware Racing across NASCAR, motocross, and hot rods, with the Naval Base Coronado race described as the first of 50 planned motorsports activations, paid in equity rather than cash. That preserves the balance sheet at a moment when balance sheet matters. It’s worth being clear-eyed that equity isn’t free; it’s dilution with a deferred settlement date, landing on a structure that already carries ~7.4 million warrants at C$0.85 expiring January 22, 2027. But trading paper for national brand exposure while cash is the scarcer input is a defensible call.
Now the part I want to flag because I think it’s misread as bad news when it’s actually confirmation:
Filed gross margin has compressed for four straight quarters, 89.2% in Q2 2025, 88.0% in Q3, 83.7% in Q4, and 75.0% in Q1 2026. Direct costs more than tripled year over year, while revenue grew roughly 44%.
That is exactly what should happen. The old revenue base was high-margin Canadian SaaS. U.S. patient visits carry real delivery cost. Margin compression is the fingerprint of the U.S. business actually mixing into the numbers, it’s the first hard evidence in the filed record that the thing I’ve been arguing would happen is happening. A company that stays at 89% is a company whose U.S. visits aren’t scaling.
The honest implication: any model holding gross margin at 88% through 2035 while projecting U.S.-dominated revenue growth is internally inconsistent, and Maxim’s does. The filed numbers are already thirteen points below that assumption. I’d rather own that now and be right about the direction than defend a number the company itself is moving away from. Lower margin on a much larger revenue base is the trade you want here.
4. Two agreements that open genuinely new service lines
The California IPA agreement (announced June 30, 2026, effective June 1). Rocket Doctor’s first value-based primary care provider agreement, alongside a specialty services agreement, with a California independent physician association. Physicians get assigned patient panels under a population-based reimbursement structure ongoing primary care and population health management rather than episodic urgent care. The specialty services piece carries in-network access to over 5 million patients across 9 payers and 65 insurance products.
Cherniak has said this work commands multiples of standard urgent care reimbursement. That’s management commentary rather than filed disclosure, and I’d note that population-based reimbursement pays for a panel rather than an encounter so it changes the unit economics in ways a simple per-visit multiple doesn’t capture. But the strategic point holds: this moves Rocket Doctor up the value chain from transactional care to continuity of care, where durable payer relationships live.
The California network agreement (announced August 18, 2026, effective July 1). One relationship, five healthcare and insurance channels, including workers’ compensation and auto medical, which Rocket Doctor had no exposure to before. The counterparty connects into a nationwide network spanning over 700 health plans, more than 100,000 employers, and close to 60 million consumers.
To be precise, because precision here is the whole basis of anyone taking my numbers seriously: that 60 million describes the network’s national footprint, and Rocket Doctor’s access under this agreement is California-scoped. Cherniak’s own framing “as we continue to scale in California” says so. The counterparty is a network lessor, not a direct payer like Aetna or Anthem. What’s genuinely additive is the channel access: workers’ comp and auto medical run on different reimbursement dynamics and different claims cycles than Medicaid managed care, and getting into both through a single relationship is efficient TAM expansion.
Filed disclosure supports approximately 21 million covered lives, California ~8.1M, New York ~9.9M, Maryland ~3.1M. Press releases since August 11 cite approximately 24 million following the New York expansion. I use the filed number until the next MD&A confirms the higher one.
The bottom line: the walls are going up
Cherniak’s analogy for where the company sits is right. For two to three years, Rocket Doctor was digging the hole and pouring the foundation. From the outside and to the market it looked like nothing was happening. That’s the phase the share price is still pricing.
The walls are now going above ground. The infrastructure is built, the payer contracts are signed, the physician pipeline is filling and paying to be there, and the marketplace is matching patients to doctors at a rate that was zero nine months ago. As credentialed physicians go live through Q3 and Q4 and the cash-basis recognition lag catches up, the revenue scaling should become visible in the filed numbers rather than only in the operating commentary.
What I’m watching to confirm it:
U.S. revenue as a percentage of total revenue. This is the thesis validation metric; everything else leads into it.
Credentialing conversion: how many of the 80+ reach billable status, and how fast.
Visits per credentialed physician per month. Signing doctors is the easy part; utilization is the business.
Gross margin finding a floor. Compression is expected. Where it stabilizes determines the modelis value.
Cash. C$3.50 million at March 31, 2026 against C$3.09 million used in operations that quarter, with financing covered by a C$4.96 million placement and C$1.23 million in warrant exercises. Capital markets dependency is a live risk regardless of how the operating metrics trend, and the escrow release calendar runs through August 2027.
None of that changes the thesis. It’s the scoreboard I’ll grade it against.
I’m long, and Q2 made me more comfortable being long, not less.
Citation: Cherniak, Dr. Bill (Co-Founder & CEO, Rocket Doctor Inc.). Q2 2026 corporate update interview. [HOST / CHANNEL], [DATE].
Additional sources: Rocket Doctor AI Inc. Condensed Interim MD&A and Interim Financial Statements for the three months ended March 31, 2026 (SEDAR+, filed June 1, 2026); GlobeNewswire releases dated June 30, August 11, and August 18, 2026; Maxim Group initiation of coverage (Klee, Greenberg); Fundamental Research Corp update (Rajeev).
Disclosure: I hold over 1.5 million shares of Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | FSE: 939), representing a meaningful portion of my equity portfolio. I have not been compensated by the company or any affiliate for this piece. NFA. DYOR.
Very pleased to see the company grow to 80+ US physicians and 4,000+ patient visits!